APA citiranje

Raedler, L. A. (2015). Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma. Am Health Drug Benefits.

Citação norma Chicago

Raedler, Lisa A. "Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma." Am Health Drug Benefits 2015.

MLA citiranje

Raedler, Lisa A. "Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma." Am Health Drug Benefits 2015.